3B Blackbio's M&A focus and contract math keep shifting between quarters
Management expanded its acquisition horizon, revised down executed Coris volumes, and repackaged a missed growth target as a base-effect story — all without acknowledging the contradictions.
What's new
- FY26 consolidated revenue was ₹142 cr, with 3B India at ₹86.47 cr (up 10% YoY).
- FY27 guidance is 15-20% consolidated growth, implying ₹175-180 cr revenue.
- Coris HAT contract executed amount revised down to €2.6 million from ₹3.45 million cited in Feb.
- M&A horizon expanded beyond IVD, with a ₹240 cr opportunity under evaluation.
Themes from the call
Execution
The Coris HAT contract's executed amount shrank by €0.85 million between calls, a math problem that went unexplained.
Guidance
FY26 domestic growth missed the 15% floor management set in Aug 2025, landing at 10%.
Strategy
M&A scope widened from molecular-only to adjacent diagnostic areas, with ₹230 cr in cash reserves to deploy.
Guidance watch
- FY27 consolidated growth guided at 15-20%, with Coris full-year contribution at ₹52 cr and 3B/TruPCR at ₹107-110 cr.
- Coris targets slightly EBITDA-positive in FY27, with margins reaching 10%+ in subsequent years.
- US FDA submission for Resis 5 is underway, with approval expected in 1-2 years and potential €1-1.5 million contribution.
Risk flags
- The Coris contract math inconsistency suggests either weak internal tracking or selective disclosure.
- Domestic growth missed guidance, and management's explanation flips its prior narrative about seasonal tailwinds.
- The ₹240 cr M&A opportunity is unnamed and undated, making the capital allocation commitment hard to assess.
Key quotes
-
"Going into any other technology which is not molecular, that's not in our agenda immediately."
— Dhirendra Dubey, CEO, Feb 2026 call -
"We are also expanding our horizon beyond the IVD industry to areas where diagnostics or genetics is a part, but not hardcore IVD."
— Dhirendra Dubey, CEO, Jun 2026 call
The brief
3B Blackbio's conference call was a study in retroactive narrative engineering. Management began the year saying M&A would stick to molecular diagnostics. This quarter, the perimeter expanded beyond IVD. The shift itself isn't the problem; the lack of explanation is.
The same pattern appears in the Coris HAT contract. In February, management said €3.45 million of the €6 million contract had been executed. This quarter, that figure dropped to €2.6 million. No correction, no clarification. For a company tracking a multi-year, high-margin government contract, the arithmetic should be precise.
Then there is the growth miss. In August 2025, management projected a minimum 15% domestic growth for FY26, citing seasonal disease spikes as a supportive tailwind. The actual number was 10%. This quarter, those same seasonal spikes were cited retroactively as creating an exceptionally tough comparable base. The same data point was used first as a tailwind, then as a headwind.
The FY27 guidance of 15-20% consolidated growth assumes Coris delivers ₹52 cr on a full-year basis and 3B India accelerates to 15% growth. The domestic business is guiding 15% in a market where it just delivered 10%. The burden of proof is on management to show why this year's target will stick when last year's didn't.
When the math and the narrative keep changing, the guidance is the least credible part of the story.